Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
N/A | Nab-paclitaxel | Gastrointestinal cancer | Active | |||
Truqap | capivasertib | HR-positive, HER2-negative locally advanced or metastatic breast cancer | Active | |||
TBC | lebrikizumab | atopic dermatitis | Active | |||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
Tagrisso | osimertinib | Non-small cell lung cancer | Active | |||
N/A | Pembrolizumab | Melanoma (Skin) | Active | |||
N/A | Nivolumab and Ipilimumab | Melanoma (Skin) | Active | |||
N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Active | ||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
Olumiant | baricitinib | Alopecia areata, severe | Active |